Update: A strong exit for 2015
Hexvix/Cysview sales grew 34% year-on-year for Q415, showing marked improvement over Q315 growth rates of 17%. The year closed with NOK115.8m in sales of Hexvix/Cysview, a 26% improvement over 2014, driven primarily by increased unit volume in the US but bolstered by a favourable currency exchange. Revenue growth for the quarter was in the double digits across all reported markets and the company ended the year with cash of NOK134m, which we see as more than sufficient to bring the company to profitability in 2018.Photocure is a Norwegian based specialty pharmaceutical company. Co. develops and commercializes solutions in several disease areas such as bladder cancer, colorectal cancer, HPV and precancerous lesions of the cervix, acne and other dermatologic conditions. Co. has one marketed product that Co. commercializes directly in the U.S. and the Nordic region is Hexvix®/Cysview®, for detection of bladder cancer.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.